Mild Cognitive Impairment/Alzheimer's Disease

Cassava
Randomized, controlled trial of simufilam, an investigational drug candidate for the treatment of patients with Alzheimer’s disease

Biogen
BIOGEN ICARE AD Study

Lilly
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
TrailBlazer 3

Lilly-closed
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
extension 9  TrailBlazer 3

Lilly-closed
Assessment of Safety, Tolerability, and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease
  
Alzheon
A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Study of the Efficacy, Safety and Biomarker Effects of Alz-801 in Subjects with Early Alzheimer’s Disease and APOE4/4 Genotype

Novo Nordisk
 A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE) 
​
 A randomised double-blind placebo-controlled clinical trial investigating the effect and safety of oral semaglutide in subjects with early Alzheimer´s disease (EVOKE plus) 


More to come.......

​
​TauRx--closed
Randomized, Double-Blind, Placebo-Controlled, Three-Arm, 12-Month, Safety and Efficacy Study of Hydromethylthionine Mesylate (LMTM) Monotherapy in Subjects with Alzheimer’s Disease followed by a 12-Month Open-Label Treatment

Ban2401--closed
A Placebo-Controlled, Double-Blind, Parallel-Group, 18-Month Study With an Open-Label Extension Phase to Confirm Safety and Efficacy of BAN2401 in Subjects With Early Alzheimer's Disease